by Claire | Oct 23, 2022 | Uncategorized
DIADEM NAMES CLINICAL DIAGNOSTICS INDUSTRY VETERAN PAUL KINNON AS CEO —Kinnon Joins to Lead Development and Commercialization of First Minimally Invasive Blood-Based Prognostic Test for Early Alzheimer’s Disease— —Accessible Early Diagnosis Will Transform...
by Claire | Oct 23, 2022 | Uncategorized
DEVELOPMENT OF BLOOD-BASED ALZHEIMER’S PROGNOSTIC PROPELS DIADEM TO FINALIST STATUS FOR BOTH THE GAETANO MARZOTTO COMPANY PRIZE AND 2030 SOCIAL IMPACT SPECIAL PRIZE —Prestigious Awards Celebrate Entrepreneurial Company Innovation and Pioneering New Products Supporting...
by Claire | Oct 23, 2022 | Uncategorized
DIADEM NAMES DR. TAMAS BARTFAI CHAIR OF ITS MEDICAL ADVISORY BOARD —Dr. Bartfai Brings Broad Academic and Pharma Industry Experience to Medical Advisory Board Comprised of Distinguished Alzheimer’s Disease Researchers and Opinion Leaders — Milan, ITALY – December 1,...
by Claire | Oct 23, 2022 | Uncategorized
DIADEM PRESENTS CLINICAL DATA AND COMMERCIALIZATION PLANS FOR ITS ALZOSURE® PROGNOSTIC BIOMARKER TEST AT 2020 ALZHEIMER’S DISEASE INTERNATIONAL CONFERENCE —Blood-Based AlzoSure Assay Has Potential to Transform Management of Alzheimer’s Disease by Identifying Patients...
by Claire | Oct 23, 2022 | Uncategorized
NEW SCIENTIFIC PUBLICATIONS SHOW DIADEM’S BLOOD-BASED ALZOSURE® BIOMARKER TEST CAN PREDICT WHICH PATIENTS WILL PROGRESS TO ALZHEIMER’S DISEASE YEARS BEFORE SYMPTOMS OCCUR —Published Studies Explore How a Variant of p53 Contributes to the Development of Alzheimer’s...
by Claire | Oct 23, 2022 | Uncategorized
DIADEM PRESENTS NEW DATA AT AAIC® SYMPOSIUM SHOWING ITS BLOOD-BASED BIOMARKER TEST ACCURATELY PREDICTS PROGRESSION TO ALZHEIMER’S DISEASE 7 YEARS BEFORE SYMPTOMS OCCUR —Analysis of 224 Longitudinal Patient Samples Confirms Diadem’s Prognostic Biomarker Can Predict...